Zongsheng Pharmaceutical: Controlled subsidiary, a class of innovative drug Anglatide Wai project two phase III clinical trials obtained positive results.

Zhongsheng Pharmaceutical announced that a class of innovative drugs developed by its controlling subsidiary Zhongsheng Ruichuang, Angladewei granules for the treatment of Type A influenza in patients aged 2-11 and Angladewei tablets for the treatment of Type A influenza in adolescents aged 12-17, have recently obtained top-line analysis data from their Phase III clinical trials. Preliminary results indicate that Angladewei granules demonstrate positive efficacy and good safety in participants aged 2-11 with Type A influenza, while Angladewei tablets show similar results in participants aged 12-17. The trial results are promising and have achieved the expected goals.